Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00645736




Registration number
NCT00645736
Ethics application status
Date submitted
25/03/2008
Date registered
28/03/2008
Date last updated
22/11/2011

Titles & IDs
Public title
CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study
Scientific title
Study of Acquired Viral Mutations in Chronic Hepatitis B Patients on Antihepadnaviral Therapy
Secondary ID [1] 0 0
GS-AU-103-0185
Universal Trial Number (UTN)
Trial acronym
CHARM
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Hepatitis B 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Other interventions - No intervention

1 - Single cohort


Other interventions: No intervention
No intervention
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Descriptive statistics for clinical and viral characteristics of the study population
Timepoint [1] 0 0
Single timepoint (blood draw)

Eligibility
Key inclusion criteria
* Aged 18 years and over
* Provided informed consent
* Diagnosis of chronic hepatitis B (HBsAg documented for at least 6 months)
* Currently prescribed antihepadnaviral therapy (including, but not limited to: lamivudine, adefovir, entecavir, tenofovir or telbivudine) for chronic hepatitis B management
* Been taking current antihepadnaviral therapy for at least 6 months prior to recruitment
* Negative tests for HIV Ab, Hepatitis C Ab and Hepatitis D Ab within the previous 2 years
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Known or suspected co-infection with HIV, Hepatitis C or Hepatitis D
* Concomitant immunosuppression / immunomodulatory therapies
* Diagnosis of hepatocellular carcinoma where anticipated life expectancy is less than 6 months
* Current participation in an interventional, blinded, pharmaceutical industry-sponsored clinical trial
* Current Child Pugh class C classification (current Child Pugh score > 9)
* Other known or suspected cause of chronic liver disease
* Any other reason that, in the investigator's opinion, participation in the study would not be in the participant's best interest.

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2008
Sample size
Target
Accrual to date
Final
788
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Gilead Sciences Pty Ltd - East Melbourne
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Gilead Sciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study has the aim of describing viral mutation profiles in patients diagnosed with chronic hepatitis B receiving antihepadnaviral therapy.
Trial website
https://clinicaltrials.gov/study/NCT00645736
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Howard Wraight
Address 0 0
Gilead Sciences Pty Ltd
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00645736